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ABSTRACT 
CD4
+
 effector T cell subsets (e.g., Th1, Th17) are implicated in autoimmune and 
inflammatory disorders such as multiple sclerosis, psoriasis and rheumatoid arthritis. For 
optimal activation, IL-6 induces Th17 polarization and signals through the membrane-
bound signal transducer, gp130. Previously, we have demonstrated that n-3 
polyunsaturated fatty acids (PUFA), when supplied in the diet or in fat-1 transgenic mice 
which generate n-3 PUFA de novo, suppress CD4
+
 T cell activation and differentiation 
into pathogenic Th17 cells. Here we report that n-3 PUFA alter the response of CD4
+ 
T 
cells to IL-6 in a lipid raft membrane-dependent fashion. Naïve splenic CD4
+
 T cells 
from fat-1 mice exhibited significantly lower surface expression of the IL-6 receptor (IL-
6R). This membrane bound receptor is known to be shed upon cellular activation in 
response to antigen; however, the release of soluble IL-6R after treatment with anti-CD3 
and anti-CD28 was not changed in fat-1 mice suggesting that the decrease in surface 
expression is not due to ectodomain release. We observed a significant decrease in the 
association of gp130 with lipid rafts in activated fat-1 CD4
+
 T cells and a 35% reduction 
in gp130 homodimerization, an obligate requirement for downstream signaling. The 
phosphorylation of STAT3, a downstream target of IL-6-dependent signaling, was also 
decreased in response to exogenous IL-6 in fat-1 CD4
+
 T cells. Our results suggest that 
n-3 PUFA suppress Th17 cell differentiation, in part, by reducing membrane raft-
dependent responsiveness to IL-6, an essential polarizing cytokine. 
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INTRODUCTION 
 Role of CD4
+ 
T cells in inflammatory diseases 
 Chronic diseases such as cancer, cardiovascular disease and stroke are currently the 
leading causes of death in the United States. Many of these diseases are linked to 
inflammation including arthritis, multiple sclerosis (1), obesity, diabetes (2) and cancer 
(3) as well as the normal process of aging (4). Effector CD4
+
 T cells, especially Th1 and 
Th17 cells play an important role in both driving and resolving inflammatory processes. 
While effector T cells act to eradicate invading pathogens, another subset of CD4
+
 T 
cells, the Tregs function to suppress T cell activation as well as prevent reactivity against 
host tissue and subsequent autoimmune disease (5). The main functions of CD4
+
  T cells 
include cytokine production and B cell activation as well as tolerance to self-antigens 
(6). CD4
+
 T cells themselves are incapable of responding to a free antigen; instead they 
require the help of an antigen presenting cell (APC) which internalizes the antigen and 
processes it for presentation to the CD4
+
T cell via the major histocompatibility complex 
(MHC).  The MHC, in turn, interacts with the T cell receptor (TCR) forming an 
immunological synapse. Th17 cells differentiate from naïve CD4
+
 T cells under the 
influence of interleukin-6 (IL-6) and TGF-β (5,7) which activate STAT3. 
Phosphorylation of STAT3 leads to translocation to the nucleus and subsequent 
activation of ROR-γt, the master regulator of Th17 transcription. IL-23R is upregulated 
on the cell surface and contributes to the maintenance and expansion of mature Th17 
cells (8). Th17 cells function primarily to stimulate a neutrophil response in the presence 
of extracellular bacteria and are characterized by the release of IL-17A, IL-17F, IL-21 
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and IL-22 (3).  
 Th17 cells play an important role in the immune response, especially in the clearance 
of extracellular bacteria and viruses (9). This occurs through the action of cytokines. 
Specifically, IL-17 is involved in stimulating granulopoiesis and neutrophil chemotaxis 
(7,10) and IL-22 works by stimulating epithelial cell proliferation to enhance epithelial 
barrier function (11). Additionally, IL-22 induces the production of REG proteins (12) 
and protective mucus (13). Finally, IL-22 works with IL-17 to induce the production of 
antimicrobial proteins (14). However, if this response is not resolved after the pathogen 
is cleared, chronic inflammation and tissue damage ensue. Specifically, chronic Th17-
mediated inflammation in the colon has been linked to the onset of inflammatory bowel 
diseases (IBD) and to colitis-associated cancer (CAC) (15). A chronic pronounced 
elevation in the IL-6/gp130/STAT3 signaling axis is considered a risk factor for 
colorectal cancer due in part to stimulation of epithelial cell proliferation (16). Further 
investigation suggests that dysregulation of IL-6 signaling leads to gastric cancer 
through a STAT3 related mechanism (17), and its inhibition can reduce tumor 
development in colitis-induced cancer model (16) and multiple sclerosis (18). 
Additionally, IL-6 present in serum prevents the polarization of T regulatory cells 
(18,19) while a deficiency in IL-6 leads to defective T cell recruitment after tissue injury 
(20). 
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Effect of n-3 PUFA on inflammation  
 Many dietary components affect the inflammatory process including n-3 
polyunsaturated fatty acids (PUFA). n-3 PUFA contain a double bond at the third carbon 
from the methyl end of the carbon chain. The human body cannot synthesize n-3 PUFA 
due to the lack of long chain desaturases that work beyond the ∆9 position (21). 
Eicosapentaenoic acid (EPA) (20:5n-3) and docosahexaenoic acid (DHA) (22:6n-3) are 
two examples of bioactive fatty acids which exhibit anti-inflammatory affects (22,23). n-
3 PUFA are known to have many health benefits including a reduction of blood 
triglycerides (24,25) blood pressure (26) and platelet aggregation (27). Αlpha-linolenic 
acid is found in leafy green vegetables, walnuts and rapeseed and flaxseed oils while 
EPA and DHA are found in marine sources such as salmon, shrimp, herring and sardines 
(28). The typical American diet contains 1.1-1.6 g/d n-3 PUFA including 110-230 mg/d 
EPA + DHA. Unfortunately, this is far below the suggested recommendation of 500 
mg/d EPA + DHA which could be accomplished by two fish meals per week (28,29). 
Previously, intake of EPA, DPA and DHA (long chain n-3 PUFA or n-3 LCFA) was 
estimated based upon food disappearance data in 42 countries. The United States ranked 
in the middle with 0.103% of energy coming from n-3 LCFA or 230 mg/d on a 2000 
kcal diet. Among the highest intakes were Iceland (0.435% of energy or 960 mg/d) and 
Japan (0.374% of energy or 831 mg/d). Bulgaria (0.023% of energy or 51 mg/d) and 
Romania (0.041% of energy or 91 mg/d) consumed the least n-3 LCFA (29). 
Epidemiological evidence suggests that populations who consume high levels of n-3 
PUFA have reduced levels of chronic inflammatory or autoimmune diseases (30). While 
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many potential mechanisms are described below to explain the role of n-3 PUFA in 
inflammation, clinical trials show mixed results. For example, some studies show 
clinical benefit (31,32,33), while others failed to improve symptoms (34,35,36). This 
could be due to differences in dose, varying ratios of ALA, EPA and DHA, length of 
study, gender or age of the subjects (37,38) or other variables such as n-6 PUFA 
consumption, type of placebo (39), and the target condition of interest. Indeed, even 
within irritable bowel disease (IBD), Crohn’s disease and ulcerative colitis often respond 
differently to n-3 PUFA treatment (39). 
In preclinical studies, n-3 PUFA suppress inflammation by several mechanisms such 
as reducing inflammatory eicosanoids, cytokines and reactive oxygen species as well as 
increasing anti-inflammatory resolvins (40). In addition, fish oil decreases obesity-
related inflammation by decreasing inflammatory hormones such as leptin and resistin 
while increasing anti-inflammatory adiponectin (41,42). Fish oil also modulates the 
genetic profile of adipose tissue and decreases CD4
+
 T cell proliferation (22,43,44,45).  
Recent evidence suggests that the anti-inflammatory effects of n-3 PUFA are 
relevant in humans. Maximal levels of membrane incorporation of EPA and DHA can be 
achieved within a week by consuming 2.4 g/d EPA and 1.2 g/d DHA (46,47). Dietary n-
3 PUFA reduce inflammatory eicosanoid production which is replaced by anti-
inflammatory or less active (48) n-3 derived eicosanoids (24,49) as well as n-3 PUFA 
derived resolvins E1 and D1 (50) which are involved in the resolution of inflammation 
through inhibition of neutrophil chemotaxis and IL-1β release (47). n-3 PUFA also 
modulate inflammatory gene expression (24) and macrophage activation in human 
5 
 
subjects (25). Recently, n-3 PUFA have been shown to reduce NF-κB activation in 
humans (51) possibly through PPARγ activation or GPR120 activation leading to 
reduced production of inflammatory cytokines (47). Finally, leukocyte chemotaxis (52), 
IL-6 (24) and T cell proliferation are reduced  in humans (53). 
   
Effect of n-3 PUFA on CD4
+
 T cells 
n-3 PUFA modulate the immune response through effects on immune cell activation 
and abundance (23,41,54). CD4
+
 T cells play an important role in the immune system by 
coordinating different cell reactions through cytokine action. During the acute phase of 
inflammation, CD4
+
 T cell activation is critical for eliciting a functional response; 
however, excessive activation can lead to tissue damage. Enrichment of n-3 PUFA in 
murine cell membranes regulates CD4
+
 T cell differentiation (23,41,54,55). Although 
mechanistic insights into the effects of n-3 PUFA on human CD4
+
 T cells are limited, it 
has been shown that n-3 PUFA reduce ex vivo proliferation of CD4
+
 T cells in humans 
(53) and this has been further probed in cell culture and animal studies. Specifically, n-3 
PUFA reduce production of IL-2, a major stimulator of CD4
+
 T cell proliferation (56) 
and gene expression of IL-2Rα (57). Furthermore, pro-inflammatory Th1 and Th17 cell 
in vivo abundance and differentiation ex vivo are reduced (23,41,54,55). Finally, 
inflammatory cytokines such as IL-17 and transcription factors such as ROR-γt are 
reduced by n-3 PUFA (41). One immunosuppressive mechanism of n-3 PUFA 
contributing to this effect may be linked to the IL-6 signaling pathway.  
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Role of IL-6R and gp130 in IL-6 signaling  
 The IL-6 receptor (IL-6R) is an 80 kDa surface protein expressed in monocytes, 
activated B cells and neutrophils as well as CD4
+
 T cells, especially in the naïve or 
memory phenotypes (58). Downstream signaling by IL-6 is mediated through several 
steps, including both classical signaling and trans-signaling. During classical signaling, 
two molecules of IL-6 bind to two membrane bound IL-6 receptors (mIL-6R) which 
form a complex with two molecules of gp130 resulting in a hexameric signaling 
complex (Figure 1, 20,59). Interestingly, many cells, such as smooth muscle and 
endothelial cells (18), do not express IL-6R, yet they still exhibit trans-signaling in 
which soluble IL-6R (sIL-6R) shed from contiguous cells binds to IL-6 and membrane 
bound gp130. Typically, sIL-6R is produced by alternative splicing or enzymatic 
cleavage of mIL-6R by ADAM17 (a disintigrin and metalloproteinase) and ADAM10 
(59,60,61).  Activation of T lymphocytes with anti-CD3 and anti-CD28 leads to down 
regulation of IL-6R on the cell surface and an increase in sIL-6R (20,59)  through the 
action of ADAM17; other activators of IL-6R shedding include PMA, bacterial 
metalloproteinases, C-reactive protein and cholesterol depletion (61). Elevated levels of 
sIL-6R seen during periods of inflammation are involved in the pathogenesis of 
rheumatoid arthritis, Crohn’s disease and colon cancer (17,19,59). Indeed, sIL-6R 
appears to be responsible for the pathophysiology of IL-6 while mIL-6R is associated 
with normal cellular functions such as acute phase protein response and B cell 
modulation (18). gp130 is ubiquitously expressed and mediates signal transduction for 
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Figure 1. IL-6 signaling through soluble and membrane bound receptors. During 
classical signaling, two molecules of IL-6 bind to two membrane bound IL-6 receptors 
which induce gp130 homodimerization and downstream activation of the JAK-STAT 
pathway leading to translocation of ROR-γt to the nucleus to activate Th17 polarizing 
genes. During trans-signaling, soluble IL-6R binds to IL-6 and membrane bound gp130 
to propagate signaling. Conversely, this pathway can be inhibited by soluble gp130 
which prevents signal transduction.  
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IL-6 and many other cytokines including IL-11 and IL-27 (17). Similar to IL-6R, gp130 
can be membrane bound (mgp130) or soluble (sgp130), where it activates JAK1, JAK2 
and tyrosine kinase 2 (Figure 1). Soluble gp130 is produced by alternative splicing or 
proteolytic cleavage (62). Soluble gp130 acts as an inhibitor of IL-6 trans-signaling by 
binding to IL-6/sIL-6R without performing subsequent signal transduction (61). Mice 
engineered to be gp130 deficient die as embryos (17,58) suggesting that gp130 is 
essential for  life. In CD4
+
 T cells, a lack of gp130 leads to a reduced Th17 response and 
an increased Treg response, resulting in protection against experimental autoimmune 
encephalomyelitis (EAE) (17). The presence of soluble gp130 in the serum also inhibits 
Th17 development (20), suggesting that gp130 is an important mediator of Th17 
differentiation. 
 
Effect of n-3 PUFA on the plasma membrane 
 n-3 PUFA  influence the structure of the plasma membrane (43,44), a highly 
heterogeneous lipid bilayer containing liquid ordered (lo) and liquid disordered (ld) 
regions (63,64,65). Liquid ordered regions, also known as lipid rafts, are enriched in 
cholesterol and sphingolipids and are insoluble in cold, nonionic detergents (65). These 
microdomains have been isolated and studied by detergent extraction and visualization 
by fluorescence microscopy. However, traditional fluorescence microscopy cannot 
visual individual rafts due to a diffraction limit of 200 nm. More recently, super-
resolution microscopy techniques have been used to visualize individual raft domains 
that are sensitive to cholesterol depletion (64). These heterogeneous microdomains are  
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small (10-200 nm) and contain many signaling proteins. Raft domains, therefore, can 
function as a signaling platforms for many cell types (63,66). Indeed, previous research 
suggests that n-3 PUFA increase the condensation of lipid rafts around the 
immunological synapse. This effect is accompanied by a modification of the 
microenvironment or more specifically the proteins that are found within the raft and 
collectively these changes lead to reduced cellular activation (43). It has previously been 
shown that expression of membrane bound receptors including IL-6R is modulated by 
the cholesterol composition of the plasma membrane (67). This may be due to the fact 
that DHA is highly unsaturated and is therefore sterically incompatible with cholesterol, 
a major component of lipid rafts (68,69). This incompatibility affects the plasma 
membrane by altering membrane fluidity, phase behavior, permeability, fusion, flip-flop 
and protein function (69). 
 Previous research shows that reducing membrane glycosphingolipids blocks Th17 
polarization without affecting other phenotypes (70) suggesting that Th17 polarization is 
modulated through a lipid raft related mechanism. These data suggest that by perturbing 
sites (domains) of high membrane dependent signaling, T cell activation is decreased. It 
has been shown that n-3 PUFA suppress the co-localization of T cell receptor signaling 
proteins into lipid rafts (43) which decreases the robustness of downstream signaling. 
With respect to IL-6 signaling, previous reports suggest that glycoprotein 130 is 
localized to lipid rafts in kidney (71) and neuroepithelial (72) cells, however, this has not 
been investigated in CD4
+
 T cells. Since IL-6 is a critical initiator of Th17 
differentiation, changes in the expression of members of the IL-6 signaling pathway can 
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drastically affect cell abundance. Indeed, a reduction in gp130 expression leads to 
significantly reduced Th17 abundance and a shift towards a Treg phenotype (17).  
Therefore, n-3 PUFA may decrease cellular responsiveness to IL-6 by altering the 
localization of gp130 in the plasma membrane.  
 
Significance 
 It is currently unknown how n-3 PUFA modulate Th17 polarization. We have 
previously demonstrated that n-3 PUFA enhance lipid raft size in CD4
+
 T cells leading 
to reduced cellular activation (69). Therefore, it is possible that lipid raft dependent IL-
6R/gp130 Th17 polarization is disrupted by a similar mechanism.  To determine the 
mechanism of n-3 PUFA action, fat-1 transgenic mice were used as a genetic model of 
dietary n-3 PUFA. 
  The fat-1 mouse contains the fat-1 gene from C. elegans and is able to convert n-6 to 
n-3 PUFA in vivo and, therefore, can be used to study dietary n-3 PUFA without the 
need for a prolonged feeding period (21). Fat-1 mice display a similar membrane 
enrichment of n-3 PUFA as a wild type mouse consuming a 4% fish oil diet (22). 
Furthermore, Th17 cell abundance is reduced in fat-1 mice similar to dietary n-3 PUFA 
(23) suggesting that the genetic model is able to duplicate the phenotypic effect of a fish 
oil diet.  
 It is possible that EPA and DHA reduce responsiveness to IL-6 through a lipid raft 
related mechanism. This would result in the reduction of Th17 differentiation because n-
3 PUFA modulate lipid raft mesodomains which contain components of the IL-6-gp130-
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STAT3 axis. Therefore, our hypothesis was that n-3 PUFA reduce Th17 differentiation 
through disruption of gp130 localization in lipid rafts and further reduction in 
downstream signaling. In order to test this hypothesis, we examined the effects of n-3 
PUFA on membrane localization of gp130, surface and gene expression of IL-6R and 
gp130, IL-6 induced gp130 dimerization and STAT3 phosphorylation in CD4
+
 T cells 
from fat-1 mice.  
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METHODS 
 
Experimental animals 
 Male and female fat-1 and wild type mice were obtained from Dr. Jing Kang, 
Harvard Medical School. Mice were bred at Texas A&M facilities, genotyped and 
phenotyped as described previously (73) and maintained on a modified AIN-76A diet 
containing 10% safflower oil (D03092902; Research Diets, New Brunswick, NJ) 
adequate in all required nutrients. Mice were maintained under barrier conditions with 
one to five mice per cage in a twelve hour light and dark cycle at 21°C. All procedures 
and protocols followed guidelines approved by the U.S. Public Health Service and the 
Institutional Animal Care and Use Committee at Texas A&M University. 
 
CD4
+
 T cell isolation & culture  
 Wild type and fat-1 mice were sacrificed by CO2 asphyxiation and spleens were 
extracted aseptically and placed in sterile MACS buffer (Miltenyi Biotec, Auburn, CA). 
Spleens were crushed with a 10 mL syringe plunger through a 70 µm plastic mesh and 
washed with MACS buffer through a 40 µm filter (BD Falcon). The subsequent cellular 
suspension was applied to a Miltenyi positive selection column (See Appendix A for 
details).  Viability was assessed by Trypan Blue exclusion and cell counts were 
determined by a Coulter counter before use in the following experiments. Cell 
stimulation was used for IL-6 induced dimerization or activation induced shedding of 
mIL-6R experiments (described below).  
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Co-localization of gp130 in lipid rafts by immunofluorescence  
 CD4
+ 
T cells were analyzed by immunofluorescence according to Kim et al (43) with 
some modifications. In order to determine activation-induced changes in gp130 and lipid 
rafts, CD4
+
 T cells were activated with 0.17 µg/mL plate bound anti-CD3 and 1.67 
µg/mL plate bound anti-CD28 (eBioscience) for 30 minutes at 37ºC and compared to an 
untreated control. For fluorescence experiments, comparison of fixation with 
paraformaldehyde (PFA) (Electron Microscopy Sciences) vs PFA plus glutaraldehyde 
(GA) (Sigma) was performed.  Cells were fixed with 4% PFA alone or 4% PFA with 
0.2% GA for 30 minutes at room temperature. For analysis of WT and fat-1 cells, freshly 
isolated CD4
+
 T cells were plated at 5 x 10
6 
per well for 30 minutes at 37ºC in poly-L-
lysine coated chamber slides before fixation with 4% PFA for 30 minutes at room 
temperature. Quenching consisted of two consecutive 10 minute incubations with warm 
(37°C) 100 mM glycine followed by permeabilization with 0.2% Triton, blocking in 
10% goat serum and overnight incubation in 10 µg/mL rat anti-mouse gp130 (R&D 
Systems, Minneapolis, MN). Following washing, cells were subsequently incubated with 
10 µg/mL Alexa 555 conjugated donkey anti-rat IgG for two hours followed by 
incubation with 6 µg/mL Alexa 488 conjugated cholera toxin (Life Technologies, 
Carlsbad, CA) for one hour. Slides were dried in a series of ethanol and xylene washes 
before being coverslipped in ProLong antifade reagent (Molecular Probes) and 
subsequent visualization using a Zeiss 510 LSM in confocal mode. Co-localization 
appeared yellow due to red (Alexa 555) and green (Alexa 488) overlap which was 
quantitatively assessed by Pearson’s correlation (43). 
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Basal gp130 protein expression by western blot 
 Basal levels of gp130 were assessed by western blot as described previously (69). To 
determine an optimal protein mass to load for the western blot, 1, 2, 4 and 8 µg of T cell 
lysate protein were applied to a 4-20% Tris-glycine gel (Expedeon) before being 
electrophoresed at 125 V for 2 hours followed by a 90 minute transfer onto a 
polyvinylidene difluoride membrane (Immobilon) at 400 mAmps. A quantity of 0.1 
µg/mL rabbit anti-gp130 (Santa Cruz) was applied overnight followed by 0.1 µg/mL 
peroxidase labeled goat anti-rabbit IgG (KPL) for one hour to detect gp130.  
Chemiluminescence was quantified using Quantity One software (Bio-Rad) on a Fluor-S 
Max MultiImager (Bio-Rad, Hercules, CA) as described previously (69). For analysis of 
WT and fat-1 protein expression, 4 µg of protein lysate was selected and processed.  
 
Quantification of gp130 and IL-6R mRNA by qPCR  
CD4
+
 T cells were isolated for RNA extraction using an RNAqueous kit (Life 
Technologies, AM1914) according to the manufacturer’s instructions followed by qPCR 
analysis as described previously (23). Briefly, freshly isolated splenic CD4
+ 
T cells were 
washed in PBS and suspended in Lysis/Binding buffer before addition of 64% ethanol. 
This suspension was applied to a spin filter and centrifuged at 13,000 rpm for 30 seconds 
before three washes with kit wash buffer 1 and wash buffer 2/3 twice followed by 
centrifugation at 13,000 rpm for 30 seconds after each wash. Pre-warmed elution buffer 
was used to recover the RNA by centrifugation at 15,000 rpm for 30 seconds. RNA 
quality was measured using a Bioanalyzer with an RIN cut-off of 8.0 or greater. 
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Quantification was assessed on a NanoDrop spectrophotometer (Waltham, MA) before 
reverse transcription was performed. For reverse transcription, a mixture of 90 ng of 
RNA, 0.25 µl hexamers, 1.25 µl oligo dT and RNase free water to a volume of 14.75 µl 
was heated to 65ºC for 5 minutes and cooled slowly to room temperature. The mixture 
was incubated at 37ºC for one hour with Superscript reverse transcriptase (Invitrogen), 
1
st
 strand buffer, dithiothreitol, dNTPs and RNase inhibitor. After incubation, the 
mixture was frozen before further analysis by real-time PCR in which a TaqMan pre-
developed assay from Life Technologies was utilized. In order to determine the optimal 
RNA mass for reverse transcription, 0.09, 0.9, 9, 90 and 900 µg of RNA were reverse 
transcribed and analyzed by qPCR as described in the Methods and the optimal 
concentration was determined by evaluation of the CT curves. 
 
gp130 and IL-6R surface expression by flow cytometry  
 The antibody concentration was determined by selecting the optimal signal to noise 
ratio. Two hundred thousand freshly isolated splenic CD4
+
 T cells were stained with 
either anti-gp130 or anti-IL-6R or the appropriate isotype control (BD Pharmingen) and 
the signal to noise ratio was determined by dividing the fluorescence intensity of the 
antibody stained cells by the fluorescence intensity of the isotype control stained cells 
and the highest ratio was selected for use. For analysis of WT and fat-1 cells, CD4
+
 T 
cells were stained with 1 µg CD 16/32 (Ebioscience) for 15 minutes at 4ºC and 0.5 µg 
anti-gp130 or anti-IL-6R (R&D and BD Bioscience, respectively) for 30 minutes on ice 
and analyzed on an Accuri flow cytometer. For activation induced shedding, cells were 
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stimulated in a 96 well plate with 5 µg/mL anti-CD3 and anti-CD28 (Ebioscience) for 48 
hours at 37°C followed by analysis of surface expression by flow cytometry. 
Supernatants were stored at -80°C for analysis of soluble receptors by ELISA.  
 
Detection of sIL-6R by ELISA  
 Soluble IL-6R was measured by ELISA (R&D Systems). In order to generate a 
threshold level of sIL-6R that could be read by the ELISA kit, 9x10
4
, 1.8x10
5
, 3.6x10
5
 
and 7.2x10
5
 CD4
+
 T cells were incubated for 48 hours in the presence or absence of 
stimuli before the supernatant was analyzed by ELISA. The incubation period was also 
optimized when 2x10
5
 cells were incubated with or without anti-CD3, anti-CD28 and 
TNF-α proteinase inhibitor (TAPI) for 24, 48 and 72 hours at 37ºC before analysis by 
ELISA. Supernatants were isolated and aliquoted after activation with anti-CD3 and 
anti-CD28 from above. In order to determine soluble receptor levels, supernatants were 
applied to a high binding 96 well plate (R&D Systems) previously coated overnight with 
1.6 µg/mL IL-6R capture antibody and blocked with  1% BSA for one hour. Following a 
two-hour incubation with the supernatants, plates were washed and 200 ng/mL 
biotinylated goat anti-mouse IL-6R detection antibody was applied for 2 hours. Finally, 
the plate was incubated with horseradish peroxidase conjugated streptavidin followed by 
equal parts of 3,3’,5,5’-Tetramethylbenzidine and hydrogen peroxide. The reaction was 
stopped with 2N sulfuric acid and the plate was read at 450 nm. Optical density at 540 
nm was subtracted from the optical density at 450 nm before sIL-6R concentration was 
calculated to account for imperfections in the plate and give a more accurate reading. 
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IL-6 induced gp130 dimerization by western blot  
 Levels of gp130 dimer were also assessed as previously described (69). Briefly, 
7x10
6
 CD4
+
 T cells were stimulated with 100 ng/mL recombinant IL-6 (Biolegend 
575704) for 15 minutes at 37°C followed by crosslinking in 3 mM 
bis(sulfosuccinimidyl)suberate (Thermo Scientific 21585) for 2 hours at 4°C. Samples 
were homogenized as described previously (69) and electrophoresed at 125 V for 3 
hours followed by an overnight transfer onto a PVDF membrane at 400 mAmps. The 
gp130 monomer appeared at 130 kDa while the dimer appeared at 260 kDa. The protein 
levels were quantified by chemiluminesence as described above. 
 
IL-6 induced STAT3 phosphorylation by ELISA  
 Freshly isolated CD4
+
 T cells were stimulated with 50 ng/mL recombinant IL-6 for 
15 minutes or 60 minutes. A cell population of 1x10
6 
cells per well were incubated in a 
96-well plate (BD Falcon) at room temperature during stimulation followed by release of 
STAT3 in Cell Lysis Mix provided by the kit over shaking at 300 rpm for 10 minutes at 
room temp. Supernatants were used for STAT3 and phospho-STAT3 assessment using 
an ELISA kit from eBioscience (85-86103) according to the manufacturer’s instructions. 
Briefly, 50 µl of sample was added to each well before addition of 50 µl total or 
phospho-STAT3 (Tyr705) antibody. After the mixture was incubated for 1 hour at room 
temperature with gentle shaking, each well was washed and 100 µl 3,3’,5,5’-
Tetramethylbenzidine plus hydrogen peroxide was added for 10-30 minutes. The 
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reaction was stopped with 100 µl 2N sulfuric acid before the plate was read on a 
spectrophotometer at 450 nm.  
 
Statistical analyses  
 Graphpad Prism (La Jolla, CA, version 6) was used to analyze experimental data 
using the Student’s t test for direct comparison of two populations or one-way ANOVA 
for multiple treatment groups with an upper limit of significance at p<0.05. Data not 
fitting a normal distribution (assessed using Graphpad Prism) was analyzed using the 
Mann-Whitney test.    
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RESULTS 
 
n-3 PUFA reduce co-localization of gp130 in lipid rafts 
 Due to recent evidence demonstrating that lipid rafts are important for CD4
+
 T cell 
activation (66,74), localization of gp130 in the plasma membrane was assessed by 
immunofluorescence. In order to determine the optimal method for fixation, freshly 
isolated, wild type CD4
+
 splenic T cells were fixed with 4% PFA or 4% PFA plus 0.2% 
GA for 30 minutes before analysis by confocal microscopy (Figure 2). Cells were 
stained for gp130 (left column) and cholera toxin subunit B (CTxB), a lipid raft marker 
(middle column). The green signal from gp130 and the red lipid raft signal were overlaid 
(right column) to visualize co-localization as well as non-specific autofluorescence. 
While cells fixed with 4% PFA (top row) predominantly displayed membrane bound 
signal, cells fixed with PFA and GA (bottom row) displayed high levels of cytosolic 
fluorescence suggesting autofluorescence. For this reason, GA was not included in the 
fixation process. After fixation with 4% PFA, WT and fat-1 splenic CD4
+
 T cells were 
visualized using confocal microscopy (Figure 3). Lipid rafts were labeled with Alexa 
488 conjugated CTxB (left column) while gp130 was labeled with Alexa 555 (middle 
column) and the two signals were overlaid (right column). The isotype control (top row) 
showed very little signal compared to WT cells (middle row) and fat-1 cells (bottom 
row) labeled with anti-gp130 suggesting very low nonspecific binding in comparison 
with anti-gp130 stained cells. Pearson’s correlation was used to quantitatively determine 
co-localization between gp130 and lipid rafts using a mathematical equation relating the  
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Figure 2. Optimization of cell fixation for immunofluorescence. Freshly isolated 
CD4
+
 T cells were fixed with 4% PFA with or without 0.2% GA. The reaction was 
quenched with 100 mM glycine before cells were permeabilized with Triton and labeled 
with anti-gp130 and CTxB.   
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Figure 3. n-3 PUFA displace gp130 from lipid rafts. After fixation with 4% PFA, 
splenic CD4
+ 
T cells were quenched with 100 mM glycine followed by incubation with 
2.7 µg/mL rat anti-gp130 or rat IgG2A overnight and 5 µg/mL Alexa 555 conjugated goat 
anti-rat IgG plus 3 µg/mL Alexa 488 conjugated CTxB for one hour before images were 
captured in confocal mode. A) Representative isotype control, WT and fat-1 images B) 
Pearson’s Correlation Coefficient (PCC) in WT vs fat-1 derived cells. Data represent 
means ± SEM, n = 80 cells from 4 WT mice and 60 cells from 3 fat-1 mice from three 
separate experiments.  
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intensity of each fluorophore in every pixel (75). Fat-1 mice (bottom row) displayed 
reduced co-localization of gp130 and CTxB compared to WT mice (bottom row, 
p=0.004) 
 
n-3 PUFA do not affect surface or total cell expression of gp130 
 Optimal antibody mass for measuring gp130 expression by flow cytometry was 
determined by signal to noise ratio. Representative histograms are shown for each 
antibody concentration compared to the isotype control (Figure 4A). A signal to noise 
ratio was determined for each concentration by dividing the fluorescence intensity of the 
antibody labeled cells by the fluorescence intensity of the isotype control (Figure 4B). 
An antibody concentration of 5 µg/mL was selected due to a high signal to noise ratio.  
Surface expression of membrane bound gp130 was assessed by flow cytometry in 
freshly isolated WT and fat-1 splenic CD4
+
 T cells. n-3 PUFA had no effect on the total 
number of cells expressing gp130 (Figure 5A). A representative histogram is also shown 
to compare gp130 fluorescence intensity between WT (black) and fat-1 (red) CD4
+
 T 
cells (Figure 5B). Quantibrite-PE beads (BD Scientific) were used to assess antibodies 
bound per cell (ABC) which was calculated by creating a standard curve of fluorescence 
intensity from the beads and converting the fluorescence intensity of each sample to the 
antibodies bound per cell. n-3 PUFA had no effect on the antibodies bound per cell or 
the average fluorescence intensity (Figure 5E). Subsequently, gene expression was 
assessed at both the mRNA and protein levels. Prior to analysis of WT and fat-1 cells, 
differing levels of cell protein were analyzed in WT splenic CD4
+
 T cells by western 
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Figure 4. Optimization of gp130 antibody level. Splenic CD4
+
 T cells were incubated 
with 0.6, 1.25, 2.5, 5 or 10 µg/mL anti-gp130 or anti-rat IgG (n=2-3 per treatment) for 
30 minutes for analysis by flow cytometry. The signal to noise ratio was determined by 
dividing the fluorescence intensity in the anti-gp130 labeled cells by the fluorescence 
intensity in the isotype control with the same level of antibody. A) Representative dot 
plots at each antibody mass and histogram of cells labeled with anti-gp130 (red) or the 
isotype control (black). B) Signal to noise ratio at each antibody mass. 
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Figure 5. Surface expression of gp130 is unaffected by n-3 PUFA. Splenic CD4
+
 T 
cells were isolated from WT and fat-1 mouse spleens and stained with 2.5 µg/mL anti-
gp130. A) and B) representative WT and fat-1 images. C) Percentage gp130
+
 cells, D) 
Overlay of WT (black) and fat-1 (red). E) Antibodies bound per cell (ABC). Data 
represent mean ± SEM, n=4 mice. 
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blot to determine linearity in order to avoid over or under saturating the reaction between 
the anti-gp130 antibody and the gp130 protein (Figure 6). Protein levels of 1, 2, 4 and 8 
µg were electrophoresed in duplicate (Figure 6A) and quantified by chemiluminescence 
(Figure 6B) and 4 µg of protein lysate was selected for analysis (Figure 7A) because 
this level was in the linear range of the reaction suggesting it was functioning most 
efficiently. Before WT and fat-1 CD4
+
 T cells were used for gene expression analysis, 
differing levels of RNA (0.09, 0.9, 9, 90 and 900 ng) were processed by reverse 
transcription to determine the linear region of the amplification reaction. An RNA mass 
of 90 ng was considered optimal (Figure 8). No change in gp130 total protein (Figure 
7B) or mRNA (Figure 7C) was detected upon comparison of splenic CD4
+
 T cells from 
WT and fat-1 mice. 
n-3 PUFA reduce IL-6 induced gp130 dimerization and STAT3 phosphorylation 
 In order to determine whether n-3 PUFA affect gp130 function, gp130 dimerization 
was induced in freshly isolated splenic CD4
+
 T cells by incubation with 100 g/ml 
recombinant mouse IL-6. After cross-linking with BS
3
, the reaction was quenched with 
glycine and the cells were processed by western blot in the same manner as basal gp130 
with the following modification. Seventeen micrograms of protein were electrophoresed 
for two hours with an overnight transfer to a PVDF membrane. During an optimization 
step, cells were either stimulated with IL-6 or left in resting conditions and duplicated 
with or without BS
3 
for cross-linking (Figure 9A).  For analysis of WT and fat-1 cells, 
stimulated cells were compared to unstimulated cells from the same animal (Figure 9B) 
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Figure 6. Optimization of protein loading for western blot. CD4
+
 T cells were 
homogenized and protein was quantified using the Coomassie Plus Protein Assay. 
Varying amounts of protein (1, 2, 4 and 8 µg) were loaded into a 12% polyacrylamide 
gel and electrophoresed for 2 hours before transfer to a PVDF membrane for 1.5 hours. 
gp130 and beta actin were detected  using antibodies from Santa Cruz and Abcam and 
detected by chemiluminescence. A) Representative image of a gel B) Fluorescence 
intensity by protein mass. Each data point represent mean ± SEM, n=2. 
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Figure 7. Basal expression of gp130 and gene expression are not affected by n-3 
PUFA. A) CD4
+ 
T cells were isolated from wild type and fat-1 mouse spleens and 
homogenized before lysates were assessed by western blot, n=8. B) gp130 levels in WT 
and fat-1 mice. Data represent means ± SEM. C) gp130 gene expression was measured 
by qPCR, data represent means ± SEM, n=5-9.  
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Figure 8. Threshold cycle by RNA mass. Differing levels of RNA were reverse 
transcribed and gene expression of A) IL-6 B) IL-6R C) gp130 and D) ribosomal 18s 
were analyzed by qPCR. Data represent mean ± SEM, n=4. 
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Figure 9. n-3 PUFA reduce IL-6 induced gp130 dimerization. CD4
+
 T cells were 
stimulated with 100 ng/mL IL-6 to induce homodimerization of gp130 and subsequently 
cross-linked with BS
3
. Negative controls for IL-6 and BS
3
 are shown. A) Positive (+BS
3
, 
+IL-6) and negative (-BS
3
, – IL-6) controls. B) Representative image of WT and fat-1 
immunoblot ± IL-6. C) IL-6 induced dimerization was decreased in fat-1 mice. Data 
represent means ± SEM of three separate experiments, and were normalized to 
individual unstimulated values, n=5.  
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to determine a percent increase due to stimulation. CD4
+
 T cells from fat-1 mice 
exhibited 35% reduced dimer formation (p=0.032) (Figure 9C). To further ascertain the 
functional status of the IL-6/gp130/STAT3 axis in the CD4
+
 T cells from fat-1 mice, 
STAT3 phosphorylation was assessed following stimulation by 50 g/ml of IL-6. CD4+ 
T cells from fat-1 mice exhibited a 30% reduction in STAT3 phosphorylation in 
response to IL-6 (Figure 10) after 15 minutes (p=0.0014) and 60 minutes (p=0.0162) of 
stimulation.  
n-3 PUFA reduce surface IL-6R expression 
 An optimal antibody concentration for IL-6R was determined as above and 5 µg/mL 
was selected for analysis. Figure 11A-E show histograms of fluorescence intensity for 
each antibody concentration compared to the isotype control. Each condition was 
conducted in triplicate and signal to noise ratios for each concentration were determined 
(Figure 11F). Surface expression of membrane bound IL-6R was assessed by flow 
cytometry in freshly isolated WT and fat-1 splenic CD4
+
 T cells. Representative 
scatterplots of flow cytometric analysis are shown (Figure 12A and B) based on side 
scatter (y-axis) and IL-6R fluorescence intensity (x-axis). Splenic CD4
+ 
T cells from fat-
1 mice displayed a 30% reduction in the percentage (p=0.023) of IL-6R expressing cells 
(Figure 12C). In order to determine the cause of this decrease, shedding of IL-6R into 
9x10
4
, 1.8x10
5
, 3.6 x 10
5
 and 7.2 x 10
5
 WT CD4
+
 T cells were incubated with anti-CD3 
and anti-CD28 for 48 hours and the supernatants were collected for analysis of sIL-6R 
the media under activating conditions was measured by ELISA. Initially, a range of by 
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Figure 10. n-3 PUFA reduce STAT3 phosphorylation. CD4
+ 
T cells were incubated 
with 50 ng/mL IL-6 for 0, 15 and 60 minutes prior to homogenization. Cell lysates were 
analyzed by western blot for phospho-STAT3 and total STAT3, n=4. Data represent 
mean ± SEM.  *Statistically different from WT (p<0.05). 
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Figure 11. Optimization of anti-IL-6R level. Splenic WT CD4
+
 T cells were incubated 
with A) 1 µg/mL B) 2.5 µg/mL C) 5 µg/mL D) 7.5 µg/mL or E) 10 µg/mL anti-IL-6R-
PE for 30 minutes before analysis by flow cytometry. F) Signal to noise ratio by 
antibody concentration from one experiment, n=3 per treatment. Data represent mean ± 
SEM.  
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Figure 12. Surface expression of IL-6R is decreased by n-3 PUFA. Splenic CD4
+
 T 
cells were isolated from WT and fat-1 mice and stained with 5 µg/mL anti-IL-6R. A) 
and B) representative WT and fat-1 images, respectively C) Overlay of WT (black) and 
fat-1 (red). D) Percentage IL-6R
+ 
cells. Data represent mean + SEM, n=11. 
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ELISA. Figures 13A shows the concentration of sIL-6R (pg/mL) from each number of 
incubated CD4
+
 T cells unstimulated, stimulated or stimulated with TNF-α protease 
inhibitor (TAPI) which inhibits α disintigren and metalloproteinase (ADAM) and 
therefore greatly reduces the shedding of IL-6R. As expected, stimulation of CD4
+
 T 
cells led to an increase in soluble IL-6R detected in the culture media (Figure 13A) and 
TAPI decreased detectable sIL-6R in a cell population of 4 x 10
6 
cells. This cell number 
was chosen because fewer cells yielded undetectable sIL-6R after treatment with TAPI 
and a higher level of cells increased apoptosis which is known to cause IL-6R shedding 
suggesting a non-specific result. Furthermore, an incubation time of 48 hours was 
selected as 24 hours did not yield an increase in sIL-6R upon cellular activation and 72 
hours led to excessive apoptosis (Figure 13B). After analysis of WT vs fat-1 cells, n-3 
PUFA had no effect on basal, activated or TAPI treated sIL-6R levels (Figure 14A). To 
further probe the effect of n-3 PUFA on IL-6R expression, mRNA was isolated from 
naïve CD4
+
 T cells and assessed by qPCR. Optimization was carried out as above. Gene 
expression did not differ (p>0.05) between WT and fat-1 T cells (Figure 14B).  
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Figure 13. Optimization of CD4
+
 T cell activation and measurement of sIL-6R. 
CD4
+
 T cells were stimulated with anti-CD3 and anti-CD28 for 24, 48 and 72 hours 
before supernatants were collected and analyzed by ELISA. A) Comparison of varying 
amounts of WT CD4
+
 T cells were incubated for 48 hours, data represent mean ± SEM, 
n=3 per condition.. B) A cell population of 4 x 10
6
 CD4
+
 T cells from WT and fat-1 
mice were stimulated over 24, 48 and 72 hours. Data represent mean ± SEM, n=4 per 
condition. 
 
36 
 
 
Figure 14. Decreased surface IL-6R is not due to increased shedding or decreased 
transcription. A) Soluble IL-6R was measured in the supernatant fluids from splenic 
CD4+ T cells activated with anti-CD3 and anti-CD28 for 48 hours. TAPI was used to 
inhibit shedding of IL-6R. Data are combined from two separate 48 hour incubations, 
n=8. B) IL-6R mRNA levels were measured by qPCR. Data represent means ± SEM, 
n=5-9. 
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DISCUSSION 
 
Uncontrolled  inflammation is implicated in many of the current leading causes 
of death in the United States (2,3). Acute inflammation is a normal and healthy process 
involved in tissue repair and clearance of pathogens; however, if unresolved, chronic 
inflammation can lead to tissue damage, insulin resistance and  disease  such as arthritis, 
diabetes and inflammatory bowel diseases (1,2,3,15). Many dietary bioactive compounds 
appear to play a role in increasing or decreasing inflammation (76,77). One such anti-
inflammatory dietary component is n-3 PUFA which reduce inflammation, in part, 
through altered eicosanoid metabolism (24,49). n-3 PUFA are incorporated into the 
plasma membrane at the expense of arachidonic acid and therefore are substituted as 
substrates for eicosanoid synthesis leading to anti-inflammatory products (24,78). Other 
mechanisms include modulation of inflammatory genes and production of anti-
inflammatory lipid modulators such as resolvins and protectins (50,78). Most of these 
mechanisms have been assessed in a murine model; however, dietary interventions in 
humans indicate an increased production of anti-inflammatory resolvins (50) including 
resolvins E1 and D1 (50) and  protectins (79). Resolvins and protectins are involved in 
resolution of inflammation through inhibition of neutrophil infiltration and production of 
IL-1β and TNF and are beneficial in inflammatory models such as colitis (47). 
Furthermore, eicosanoid  metabolism is shifted from a reduction in proinflammatory 
eicosanoids (24,80) such as 2-series prostaglandins and 4-series leukotrienes (81), to an 
increase in less biologically active n-3 PUFA derived 3-series prostaglandins (82) and 5-
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series leukotrienes (83) Additionally, dietary n-3 PUFA reduces inflammatory gene 
expression, e.g., IL-6, HIF1α and TGFβ1, and increases in anti-inflammatory 
adiponectin mRNA (24).  TNF-α, IL-1β and IL-2 appear to be reduced while the anti-
inflammatory cytokine IL-10 is increased by fish oil supplementation (84,85,86,87). In 
human neutrophils, n-3 PUFA reduce respiratory burst in older individuals (38) and 
superoxide generation in healthy volunteers (88). Furthermore, antigen presentation 
capability is reduced in human monocytes after fish oil supplementation (89). Finally, 
diets enriched in n-3 PUFA reduce  T  lymphocyte proliferation in response to the 
polyclonal mitogen Con A (53). These results suggest that n-3 PUFA are capable of 
acting upon the human immune system to favorably modulate immune activation and 
inflammation. 
 CD4
+
 T effector cells e.g. Th1, Th2 and Th17 cells, are involved in stimulating the 
immune response for pathogen clearance, while CD4
+
 regulatory T cells (Tregs) are 
involved in immune suppression after a threat is resolved or during an attack on host 
cells (90,91,92). Recent preclinical work has focused on Th1 and Th17 cells which 
mediate autoimmune and inflammatory conditions (9,90). For example, Th17 cells are 
associated with diseases such as arthritis, irritable bowel disease and multiple sclerosis 
(93) evidenced by elevated levels in the blood of IBD patients (94,95), as well as the 
blood and synovial fluid of patients with rheumatoid arthritis (96). Protection from 
experimental autoimmune encephalitis (EAE) (97), an animal model of multiple 
sclerosis is conferred in IL-6 deficient mice. This is significant because IL-6 is critical 
for Th17 development suggesting that EAE is dependent, in part, by a Th17 response. 
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Finally, IL-17 deficient mice are resistant to collagen-induced arthritis (92). With respect 
to diet, n-3 PUFA reduce systemic and local Th1 (54,98) and Th17 abundance as well as 
ex vivo differentiation of naïve CD4
+ 
T cells into a Th17 phenotype (23,41,55). While a 
reduction in Th17 differentiation by n-3 PUFA has not been confirmed in humans, 
clinical trials show a reduction in inflammatory cytokines including TNF-α (84), IL-1β 
(49), IL-2 (85) and IL-6 (24,86). Common anti-inflammatory treatments include non-
steroidal anti-inflammatory drugs (NSAIDs) such as aspirin. These drugs are very 
effective in reducing pain by decreasing pro-inflammatory prostaglandin synthesis; 
however, negative side effects can also be present with the most common being 
gastrointestinal disturbances. For example, up to 40% of regular NSAID users may 
experience dyspepsia, nausea, vomiting, abdominal pain and heartburn and about 10% of 
long term users will have to stop treatment due to these effects (99). It is therefore 
necessary to determine innocuous dietary compounds that can reduce inflammation 
without causing negative side effects. 
 This study used transgenic fat-1 mice which generate n-3 PUFA from n-6 PUFA de 
novo due to an n-3 fatty acid desaturase from C. elegans (21). These mice have been 
shown to incorporate n-3 PUFA into the plasma membranes of  CD4
+
 T cells to the same 
extent as mice on a 4% fish oil diet (100). These data suggest that the fat-1 mouse 
faithfully recapitulates the phenotype seen in conventional mice fed an n-3 PUFA 
enriched diet and is therefore a valid model for the study of the effect of n-3 PUFA on T 
cell biology. A human equivalent dose for a mouse on a 4% FO diet was calculated as 
described previously (101). A 30 g mouse typically consumes 45 mg/d EPA + DHA 
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which is converted to 1500 mg/kg/d. This can be converted to a human dose using a Km 
factor determined by dividing weight by body surface area. The mouse Km factor, 3, was 
divided by the human Km factor, 37, and the subsequent number was multiplied by the 
1500 mg/kg/d consumed by a mouse to get an average consumption by a human. This 
was multiplied by the average 70 kg human weight to achieve a human equivalent dose 
of 8.5 mg/d. This is much higher than the current 0.13-0.17 g/d EPA + DHA (28) 
consumed by Americans although it is lower than what is consumed by the Greenland 
Inuit, whose diet contains approximately 6 to 14 g/d n-3 PUFA including ALA, EPA and 
DHA (102,103).  
 Th17 effector cells require IL-6 and TGF-β for differentiation (5,104). IL-6 binds to 
membrane bound or soluble (IL-6R) which in turn binds to membrane bound gp130. 
Together with another IL-6/IL-6R/gp130, a hexameric signaling structure is formed and 
downstream signaling is accomplished through phosphorylation of JAK and STAT3 and 
subsequent dimerization of STAT3 before translocation  to the cell nucleus and 
activation of ROR-γt, the master regulator of Th17 differentiation (60,105). Blockade of 
the IL-6R in vivo inhibits the development of a Th17 phenotype resulting in a protective 
effect in experimental autoimmune encephalitis (EAE) (106); this disease is also blocked 
by deletion of STAT3 (107) further suggesting that modulation of the IL-6-gp130-
STAT3 signaling axis can affect inflammatory diseases by altering Th17 action.   
Although it has been shown that n-3 PUFA reduce in vivo Th17 cell abundance and 
ex vivo differentiation, the mechanism is currently unknown. Based upon the evidence 
that membrane lipid raft modulation disrupts Th17 development (70), and that gp130, an 
41 
 
essential mediator of IL-6 signaling, localizes to lipid rafts (71,72), we hypothesized that 
n-3 PUFA reduce Th17 differentiation by interfering with IL-6 signaling in a lipid raft-
dependent fashion. We therefore assessed gp130 expression at the cell surface, total 
protein and mRNA levels as well as the functional capacity of the signaling axis through 
gp130 dimerization and STAT3 phosphorylation. Measurement of surface IL-6R 
expression under basal conditions and following T cell activation were evaluated 
following incorporation of n-3 PUFA.  
Currently there is disagreement regarding the exact mechanism by which n-3 PUFA 
acts on lipid rafts (108). DHA is sterically incompatible with cholesterol and would 
therefore be inserted into the bulk domain and enlarge lipid rafts by forcing cholesterol 
into raft domains. Differential scanning calorimetry and pressure-area isotherms 
experiments have supported this theory (109). However, this disagrees with evidence 
suggesting that DHA can be inserted directly into the lipid raft region based on 
quantitative microscopy techniques (110). It has been suggested that these opposing 
ideas can be combined wherein the addition of DHA to lipid rafts causes a structural 
segregation of DHA rich regions within the raft which are distinct from DHA poor 
regions. This segregation leads to rearrangement of proteins in or out of the raft region 
(108). By stabilizing lipid rafts at the immunological synapse, n-3 PUFA suppress the 
ability of signaling proteins to interact and effectively function as a signaling platform. 
Therefore, the first aim of this study was to measure the lipid raft localization of gp130, 
a critical co-receptor and signal transducer in the IL-6 signaling pathway. IL-6 and  
TGF-β are  essential stimuli for Th17 differentiation (111) and previous studies 
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suggested that gp130 is localized in liquid ordered domains in kidney and 
neuroepithelial cells (71,72). We showed that n-3 PUFA did not affect mRNA, cellular 
(Figure 7A, B, C) or surface expression of gp130 (Figure 5). However, our results 
demonstrate that n-3 PUFA reduce localization of gp130 to lipid rafts (Figure 3). This is 
noteworthy, because lipid rafts act as signaling platforms for CD4
+
 T cell activation and 
a decrease of gp130 localization in these mesodomains could lead to a reduction in 
signaling capacity. 
 gp130 homodimerization is a critical component of the IL-6-gp130-STAT3 axis and 
dimerization can be used as a functional measure of signaling capacity. For this reason, 
IL-6 induced gp130 dimerization was measured in the splenic CD4
+
 T cells from WT 
and fat-1 mice to determine if this critical step was disrupted by n-3 PUFA. Fat-1 mice 
exhibited a highly significant (p=0.032) 35% reduction in gp130 dimerization (Figure 
9), indicating that the functional ability of the protein is decreased. Furthermore, IL-6 
induced STAT3 phosphorylation, a measure of signaling activity through the IL-
6R/gp130 axis, was also significantly reduced (p<0.05) in CD4
+
 T cells from fat-1 mice 
(Figure 10).  
 This is the first report to document that the ability of n-3 PUFA to alter the 
membrane localization of gp130 in lipid rafts is associated with a reduction in IL-6 
induced gp130 dimerization and STAT3 phosphorylation. We also observed a significant 
reduction (p=0.023) in the surface expression of IL-6R in the  splenic CD4
+
 T cells from 
fat-1 mice which suggests a second, independent mechanism by which n-3 PUFA might 
interfere with differentiation of Th17 cells (Figure 12). There are a number of possible 
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mechanisms that might account for this reduction including increased receptor shedding 
upon cellular activation, reduced production of mRNA or total protein, receptor 
internalization or altered trafficking of the receptor to the cell surface. In this study, we 
determined that the reduction in in IL-6R surface expression was  not due to increased 
shedding of IL-6R upon activation (Figure 14A) or a decrease in IL-6R mRNA 
production (Figure 14B). Future work will focus on elucidating the mechanism by 
which n-3 PUFA reduce IL-6R surface expression. 
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CONCLUSIONS 
 
 Figure 15 shows the mechanistic model for the suppression of Th17 differentiation 
by n-3 PUFA. A typical membrane contains liquid ordered (lipid rafts) and liquid 
disordered regions. gp130 is localized in both raft regions and non-raft regions. During 
basal conditions some IL-6 is present and IL-6R exists both in the membrane and in the 
plasma. With an n-3 PUFA diet, raft regions enlarge and become more stable. gp130 
localization in lipid rafts is decreased leading to reduced dimerization and downstream 
activation of STAT3. Finally, membrane bound IL-6R is decreased without a subsequent 
increase in soluble IL-6R. These changes lead to reduced Th17 differentiation with n-3 
enrichment. In summary, our results indicate two novel mechanisms by which n-3 PUFA 
interfere with Th17 differentiation in vivo and ex vivo. By reducing co-localization of 
gp130 in lipid rafts in the CD4
+
 T cell membrane, n-3 PUFA attenuate the signaling 
capacity of the IL-6-gp130-STAT3 axis as evidenced by reduced gp130 dimerization 
and STAT3 phosphorylation (Figure 15). Furthermore, the ability of n-3 PUFA to 
reduce IL-6R surface expression is consistent with a decreased cellular responsiveness to 
this essential Th17-inducing cytokine. Our findings provide new insights into the 
mechanism by which n-3 PUFA suppress Th17 cell differentiation and add to the other 
mechanisms by which n-3 PUFA are known to suppress inflammation (78,112). Current 
anti-inflammatory treatments such as NSAIDS or glucocorticoids are expensive and 
often involve serious side effects (113,114). Given the high proportion of the population 
which is afflicted by inflammation; it is important to identify innocuous anti-
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inflammatory dietary compounds that could ameliorate inflammatory conditions and 
improve the health of this population. n-3 PUFA  reduce CD4
+
 T cell  activation and the 
pro-inflammatory differentiation and functions of effector Th1 and Th17 subsets 
(23,41,54,55). Understanding the precise mechanisms of these beneficial effects is 
critical to making informed decisions about recommendations for n-3 PUFA 
consumption in the diet or as supplements.  This study has added new insights to that 
body of knowledge. 
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Figure 15. Mechanistic model describing the effects of n-3 PUFA on Th17 differentiation. The IL-6 
signaling pathway is displayed in a cell membrane leading to Th17 differentiation. Different domains of 
the plasma membrane are denoted by color where brown is the bulk domain and green shows a lipid raft 
enriched in cholesterol (orange) and unsaturated fatty acids (black). A) In a WT mouse, IL-6 binds to IL-
6R leading to gp130 dimerization and a hexameric signaling structure. Upon phosphorylation, STAT3 
translocates to the nucleus to induce Th17 differentiation. B) In the fat-1 mouse, n-3 PUFA reduce gp130 
co-localization and surface IL-6R expression which lowers cellular responsiveness to IL-6, evidenced by 
reduced gp130 dimerization and STAT3 phosphorylation. This leads to reduced Th17 differentiation.  
A 
+n-3 PUFA 
Normal Th17 
differentiation 
Reduced Th17 
differentiation B 
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APPENDIX A 
 
ISOLATION OF CD4
+
 T CELLS USING MILTENYI BEAD/COLUMN  
 
Reagents: 
Scissors and forceps for animal surgery 
70 µm Cell Strainer (BD 352350) 
30 µm MACS pre-separation filter (Miltenyi 08-771-2) 
MACS separation LS columns (Miltenyi 130-042-401) 
5 mL Syringes  just need the plunger part (BD 309646) 
QuadroMACS Separation Unit (Miltenyi 130-090-976) 
100 mm Petri dish (BD 351029) 
Auto MACS Running Buffer (Miltenyi 130-091-221) 
CD4 (L3T4) Microbeads, mouse (Miltenyi 130-049-201) 
PBS (Gibco, 14190) 
RPMI (Irvine Scientific, 9159) 
Heat-inactivated FBS (Irvine Scientific, 300320439) 
Glutamax (Gibco, 35050-061) 
Penicillin-Streptomycin (Gibco, 15140-148) 
Isoton Fluid (Beckman Coulter) 
Specialty clear pipette tips (Fisher Scientific, 21-375-12) 
 
 
Procedure: 
1. Aliquot 50ml MACS buffer and RPMI media (if needed) and keep on ice before 
beginning. 
2. Remove the spleen from a mouse and place the spleen in 15 mL conical tube 
containing 3 mL of MACS buffer. 
a. Remove as much fat as possible from the spleen. 
3. Place 70 μm cell strainer inside a 100 mm Petri dish and wet the membrane by 
adding 5 mL of MACS buffer. 
4. Place a 30 μm MACS pre-separation filter on top of a new 15 mL conical tube.  
Wet the filter with 2 mL MACS buffer. 
5. Transfer the spleen with the 3 mL MACS buffer onto the cell strainer and use the 
plunger to mesh (gently push, not grind) the tissue inside the Petri dish. 
a. Keep the tissue wet at all times. 
b. Continue until only connective tissue is left on the membrane. 
c. Use Petri dish or else cells will adhere to the plate. 
6. Wash the plate with the MACS buffer in the Petri dish. 
7. Remove the cell strainer and transfer the 8 mL of buffer containing cells onto the 
30 μm MACS pre-separation filter slowly (small volume at a time to prevent 
clogging). 
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8. Wash the cell strainer by washing it inside the Petri dish with 5 mL of MACS 
buffer.  Wash the Petri dish again, and apply to the 30 μm MACS pre-separation 
filter. 
9. Remove the filter, close the lid, and gently invert the tube.  Take 20 μL and count 
using Coulter counter (4 μm cut off).   
10. Centrifuge cell suspension at 300 x g for 10 min and use a plastic tip to aspirate 
off the supernatant. 
11. Tap the bottom of the tube to loosen the pellet and then add 90 μL/107 total cells 
of MACS buffer to get a good suspension. 
a. Know the amount of cells by using the Coulter counter.  The approximate 
volume of cells is 13.5 mL (some is lost in wetting the membranes). 
b. Can only load up to 2 x 109 total cells (108 labeled cells) per LS column. 
c. Make sure to record the starting cell numbers for calculating yields. 
12. Add 10 μL/107 total cells of CD4 (L3T4) microbeads directly into the 
suspension. 
13. Mix well by pipetting and incubate for 15 min at 4 °C (use refrigerator, do not 
shake). 
14. Wash cells by filling up the 15 mL conical tube with cold MACS buffer.  Mix by 
inversion, centrifuge at 300 g for 10 min, and then use a plastic tip to aspirate off 
the supernatant. 
15. Tap the bottom of the tube to loosen the pellet and then add 500 μL/108 total cells 
of MACS buffer to get a good suspension.  
16. Snap the LS column into the QuadroMACS Separator. Orient the column so that 
the smooth side goes into the separator. Place a basin under the column for 
waste.  Pre-wet the LS column with 500 μL of cold MACS buffer.  Let the buffer 
slowly drip through. 
17. Apply the cell suspension onto the column. 
a. Can collect the flow-through to collect CD4- cell population. 
18. To rinse column, first wash the tube from Step 16 with 9 mL of cold MACS 
buffer and then apply 3 mL to the column.  Allow the buffer to run through the 
column before applying an additional 3 mL twice. 
a. This washes the unlabeled cells through the column. 
19. Remove the columns from the separator and place it on 15 mL conical tube for 
collection. 
20. Pipette 5 mL of cold MACS buffer onto the column.  Immediately flush out by 
applying the plunger supplied with the column.  Push the plunger into the column 
all the way. 
a. This fraction contains the magnetically labeled cells. 
21. Fill the tube with an additional 5 mL of cold MACS buffer.  Invert to wash well. 
22. Centrifuge the elution at 300 g for 10 min.  Aspirate off the supernatant. 
23. Fill the tube with 10 mL of ice cold PBS.  Wash by inversion. Take 20 μL of the 
suspension and count using the Coulter Counter. Use trypan blue and a 
hemacytometer to measure viability as well.  
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24. Centrifuge the elution at 300 g for 10 min.  Aspirate off the supernatant.  Proceed 
to downstream applications. 
Notes: 
 All the steps are performed in cell culture hood except the removal of the spleen 
from the mouse. 
 Store and use MACS buffer on ice, but perform rest of procedure at room 
temperature. 
 Pour out 50 mL of MACS buffer into a conical tube so that the stock MACS does not 
get contaminated. 
 Remember to prepare the Isoton Fluid the day before (dispense 10 mL into the 
cuvette and let sit to get rid of air bubbles). 
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APPENDIX B 
 
FLOW CYTOMETRY SURFACE STAINING PROTOCOL 
 
Purpose: To measure surface expression of membrane bound receptors (IL-6R and 
gp130) in mouse CD4
+
 T cells. 
Reagents:  
RPMI (Irvine Scientific, 9159) 
Heat-inactivated FBS (Irvine Scientific, 300320439) 
Glutamax (Gibco, 35050-061) 
Pen-strep (Gibco, 15140-148) 
Flow cytometry staining buffer (eBioscience #00-4222-26) 
96 well round bottom plate (BD Falcon #353077) 
Anti-IL-6R (BD #554462) or anti-gp130 (BD Pharmingen 554462) 
FC Block (eBioscience 14-0161-86) 
Flow cytometry micro tubes (BioRad #223-9391) 
 
Procedure: 
1. Make complete RPMI consisting of 1L RPMI, 100 mL heat-inactivated FBS, 11 
mL Glutamax and 11 mL Pen-strep.  
2. Isolate CD4+ T cells from mouse spleen according to Miltenyi protocol. 
3. Resuspend cells in complete RPMI to a final concentration of 1 million viable 
cells per mL. 
4. Seed 200 µl of cells in complete RPMI into each well of a 96-well round bottom 
plate. 
5. Centrifuge the plates at 350xg for 2 minutes at 4˚C 
6. Aspirate the top ¾ of the fluid with an 8 channel pipette leaving approximately 
50 µl in each well.   
7. Replace the lid back on the plate and gently tap all four sides of the plate 
multiple times to disrupt the pellet (don’t spill fluid onto lid).   
8. Add a maximum of 180 µl of flow cytometry staining buffer to each well.   
9. Centrifuge the plates at 350xg for 2 minutes at 4˚C.   
10. Aspirate the top ¾ of the fluid with an 8 channel pipette leaving approximately 
50 µl in each well and gently tap the plate to disrupt the pellet.  
11. Add 50 µl staining buffer to each well.  
12. Add 2 ul of FC block to each well and incubate at 4ºC for 15 minutes.  
13. Add flow antibody (need to optimize antibody mass first) to stained wells and 
incubate on ice protected from light for 30 minutes. 
 -0.5 µg each of anti-IL-6R and anti-gp130  
14. Wash by adding 100 µl of staining buffer and centrifuge at 350xg for 2 minutes 
at 4˚C. 
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15. Aspirate the top ¾ of the fluid with an 8 channel pipette leaving approximately 
50 µl in each well and gently tap the plate to disrupt the pellet.  
16. Add 180 µl of staining buffer and centrifuge at 350xg for 2 minutes at 4˚C. 
17. Aspirate the top ¾ of the fluid with an 8 channel pipette leaving approximately 
50 µl in each well and gently tap the plate to disrupt the pellet.                                       
18. Transfer the contents of each well to a flow micro tube and keep on ice protected 
from light. 
19. Run all samples on the Accuri right away 
 
Note: How to use Quantibrite (BD) Beads 
 
1. Keep beads in foil pouches stored at 2°-8°C before use.  
2. Reconstitute beads in buffer (PBS with 0.5% BSA plus a sprinkle of sodium 
azide-use as little as possible for this small volume) before use. Beads are stable 
for 24 hours but make as close to use as possible. 
3. Vortex quickly and run on Accuri with the same settings as samples (in this case 
run on slow) and collect 10,000 events. 
4. Parameters should be SSC-H (y-axis) vs FSC-H (x-axis). 
5. Gate around the bead singlets (see the technical data sheet for assistance) 
6. Create a histogram with count on the y axis and FL2 on the x axis. Adjust the 
markers around each population (see below figure). 
 
 
 
7. Graph the log10 geometric mean for each population against the log10 lot specific 
PE values (on the box). 
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8. Calculate the antibodies bound per cell (x) using the median channel 
fluorescence for each sample as the ‘y’ in the equation (see technical data sheet 
for mathematical help)\ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0.9448x + 0.3632 
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APPENDIX C 
 
MEASUREMENT OF ACTIVATION INDUCED CHANGES IN SOLUBLE AND 
 
SURFACE IL-6R IN MOUSE CD4
+
 T CELLS 
 
Purpose: We have previously shown a decrease in surface expression of IL-6R in 
fat-1 mice CD4
+
 T cells. We aim to determine if this change is due to increased 
shedding to soluble IL-6R. We will therefore measure surface expression as well as 
soluble IL-6R at time 0, 24hr, 48hr and 72hr.  
References: 
R&D Protocol for Mouse IL-6R alpha DuoSet, 15 Plate (#DY1830) 
 
Reagent: 
96 well round bottom plate (BD Falcon #353077) 
Anti-CD3 (BD #553057) 
RPMI (Irvine Scientific, 9159) 
Heat-inactivated FBS (Irvine Scientific, 300320439) 
Glutamax (Gibco, 35050-061) 
Pen-strep (Gibco, 15140-148) 
TNF-α protease inhibitor (TAPI) (Santa Cruz sc-203410) 
DMSO (Sigma D8418) 
β-mercaptoethanol (Sigma, M7522) 
Anti CD28 (eBioscience #14-0281-86) 
Flow Cytometry Staining Buffer (eBioscience #00-4222-26) 
Anti-IL-6R (BD #554462) 
Fc Block (eBioscience 14-0161-86) 
Quantibrite PE Beads (BD 340495) 
.  
Procedure: 
 
1. THE DAY BEFORE: Dilute anti-CD3 in sterile PBS to a final concentration of 
5µg/ml (1:200 dilution) and coat activated wells overnight at 4˚C. Maintain 
sterility by not lifting the lids off the plates when outside the hood. 
 
2. Also the day before: Make complete RPMI based on recipe below by adding 
FBS, Glutamax and Pen-strep to a 1L bottle of RPMI.  
 Volume  (mL) % Stock Concentration Final Concentration 
RPMI  1,000 88   
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Heat-inactivated FBS  100 10   
Glutamax  11 1 200 mM 2 mM 
Pen-strep  11 1 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Day 1 
3.  Resuspend 1 mg TAPI in 200 ul  (0.22 µm filterered) DMSO to make a 5 mg/mL 
 solution.  
4. Make 50 µM β-mercaptoethanol. First dilute 1 µl of the 10 mM stock with 1.43 
ml complete RPMI. Then dilute 1:200 with 50 ml complete RPMI and 250 µl 
10mM β-mercaptoethanol.  
5. Purify mouse splenic CD4+ T cells according to Appendix A Isolation of CD4+ T 
cells Miltenyi bead/column.  
6. Use a 96-well round bottom plate and adjust to 4 million cells per mL in 
complete RPMI with 50uM 2-mercaptoethanol. Cell counts must be assessed 
using the hemocytometer and viability is assessed by Trypan blue exclusion. 
7. Make two master mixes to add to each well. For each well of activated cells, add 
2 µl anti-CD28 (final concentration=5 µg/mL) and 0.9 µl DMSO in 97.1 µl 
complete RPMI. For each activated well receiving TAPI, add 2 µl anti-CD28 and 
0.9 µl TAPI in DMSO in 97.1 µl complete RPMI.   
8. Add 100 µl of cells to each well. Add the appropriate master mix (complete 
RPMI for unstimulated cells). Incubate at 37°C for 48 hours.  
9. Centrifuge cells for 5 minutes at 4ºC at 350xg and aspirate 180 µl of supernatant 
from each well for ELISA analysis (store at -80ºC).  
10. Analyze surface expression of IL-6R by flow.  
 
Soluble receptor ELISA 
Reagents: 
IL-6R ELISA kit (R&D DY1830) 
96 well microplate (high binding) (R&D DY990) 
3, 3′,5,5′-Tetramethylbenzidine (TMB) (Biolegend 421501) 
Stop Solution-2 N H2SO4 (Fisher Scientific SA213) 
  
Procedure: 
Day Before 
1. Dilute the Capture Antibody to the working concentration in PBS without carrier 
protein. Stock concentration is 288 g/mL of goat anti-mouse sIL-6R when 
reconstituted with 1.0 mL of PBS.  
2. Dilute to a working concentration of 1.6 g/mL in PBS, without carrier protein 
(1:180 dilution).  
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3. Immediately coat a 96-well high binding microplate with 100 µl per well of the 
diluted Capture Antibody. Seal the plate and incubate overnight at room 
temperature. 
(Day 1) 4.  Aspirate each well and wash three times with 400 µl wash buffer. Complete 
removal of liquid at each step is essential for good performance. After the last wash, 
remove any remaining wash buffer by aspirating or by inverting the plate and blotting it 
against clean paper towels. 
4. Block plates by adding 250 µL of Reagent Diluent to each well. Incubate at room 
temperature for 1 hour. 
5. Repeat the aspiration/wash as in step 4. The plates are now ready for sample 
addition. 
6. Add 100 µL of sample or standards in Reagent Diluent per well. Cover with an 
adhesive strip and incubate 2 hours at room temperature. 
a. Each vial of standards contains 130 ng/mL of recombinant mouse sIL-6R 
when reconstituted with 0.5 mL of Reagent Diluent. Allow the standard 
to sit for a minimum of 15 minutes with gentle agitation prior to making 
dilutions. A seven point standard curve using 2-fold serial dilutions in 
Reagent Diluent and a high standard of 3000 pg/mL is recommended. 
7. Repeat the aspiration/wash as in step 4. 
8. Add 100 µL of the detection antibody, diluted in reagent diluent, to each well. 
Cover with a new adhesive strip and incubate 2 hours at room temperature. 
a. Detection antibody stock is 36 µg/mL of biotinylated goat anti-mouse 
sIL-6R when reconstituted with 1.0 mL of reagent diluent.  
b. Dilute to a working concentration of 200 ng/mL in reagent diluent 
9. Repeat the aspiration/wash as in step 4. 
10. Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the 
plate with aluminum foil to protect form light and incubate for 20 minutes at 
room temperature.  
a. Streptavidin-HRP consists of 1.0 mL of streptavidin conjugated to 
horseradish-peroxidase. Dilute to the working concentration specified on 
the vial label using reagent diluent. 
11. Repeat the aspiration/wash as in step 4. 
12. Add 100 µL of TMB to each well. Incubate for 20 minutes at room temperature. 
Avoid placing the plate in direct light. 
13. Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough 
mixing. 
Determine the optical density of each well immediately, using a microplate 
reader set to 450 nm with wavelength correction at 540 nm. 
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APPENDIX D 
 
RNA ISOLA FROM CD4
+
 T CELLS 
 
Purpose: To extract RNA from CD4
+
 T cells for PCR analysis of gene expression.  
Reagents: 
RNAqueous Kit (Ambion AM1914) 
DNase (Life Technologies AM 1906) 
 
Procedure: 
1. Prepare 64% ethanol solution (38.4 mL 100% ethanol (ACS grade or equivalent) 
to the “Water for 64% Ethanol” bottle.  
2. Prepare wash solution #2/3 (64 mL 100% ethanol to “Wash Solution #2/3 
Concentrate”) 
3. Clean bench and pipets with an RNase decontamination solution and change 
gloves frequently throughout.  
4. Follow Appendix A Isolation of CD4+ T cells Miltenyi bead/column 
5. Collect cells in an RNase free 1.5 mL tube. Centrifuge at 350 x g for 10 min at 
4ºC.  
6. Aspirate supernatant and wash cells with 1mL PBS. Centrifuge at 350 x g for 10 
min at 4ºC. 
7. Aspirate supernatant and add 500 µl lysis/binding solution. Vortex lysate 
vigorously (may need to sonicate or pass through a 25 g syringe needle) and store 
at -80 if not isolating RNA that day.  
8. For RNA Isolation: Heat an aliquot of elution solution (50 µl per sample) in an 
RNase-free microcentrifuge tube to 70-80 °C.  
9. Reduce viscosity of lysate (by sonication, homogenization or syringe) if 
necessary (should be ~as viscous as 50% glycerol) 
10. If using more than 107 cells, centrifuge for 2-3 minutes at 13,000 rpm in a 
microcentrifuge to remove debris.  
11. Add 500 µl 64% ethanol to lysate and mix gently by pipetting or vortexing.  
12. Add lysate/ethanol mix to filter cartridge in a collection tube. Max volume that 
can be applied is 700 µl. 
13. Centrifuge at 13,000 rpm for 30 sec until mixture is through the filter. 
14. Discard flow through and repeat once more until entire 1mL goes through filter.  
15. Add 700 µl Wash solution 1 to filter cartridge 
16. Centrifuge at 13,000 rpm for 30 sec until mixture is through the filter. 
17. Discard flow through and add 500 µl Wash solution #2/3.  
68 
 
18. Centrifuge at 13,000 rpm for 30 sec until mixture is through the filter. 
19. Discard flow through and add a second 500 µl of Wash solution #2/3.  
20. Centrifuge at 13,000 rpm for 30 sec until mixture is through the filter. 
21. Discard flow through and centrifuge once more for 1 minute to remove last traces 
of wash solution. 
22. Put filter cartridge into a new collection tube. Add preheated elution solution 50 
µl to center of filter and close cap.  
23. Recover eluate by centrifugation for 30 seconds at 13,000 x g.  
24. Add 5 µl 10X DNase I Buffer and 1 ul DNase I and mix. Incubate at 37ºC for 20-
30 minutes.  
25. Resuspend DNase inactivation reagent by flicking and vortexing. Add 5 µl 
DNase inactivation reagent and mix well. Incubate for 2 minutes at room temp, 
mixing 2-3 times.  
26. Centrifuge at 10,000 x g for 1.5 minutes and transfer supernatant (contains RNA) 
to fresh RNase-free tube.  
27. Measure RNA yield and purity by nanodrop and bioanalyzer.  
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APPENDIX E 
 
IMMUNOFLUORESCENCE IN CD4
+
 T CELLS 
 
Purpose: To measure the co-localization of surface proteins (gp130) with lipid rafts 
in CD4
+
 T Cells 
 
Reagents: 
No. 1.5 Coverglass (Corning, 2935-225) 
Lab-Tek II 2-well glass chamber slide (Nalge, 154461) 
Anti-CD3 (eBioscience, 16-0031-85) 
Anti-CD28 (eBioscience, 14-0281) 
Primary Antibody-Rat anti-mouse gp130 (R&D MAB4681) 
Secondary Antibody- Alexa 555 goat anti-rat IgG (Invitrogen A21434) 
Rat IgG2A Isotype Control (R&D MAB006) 
Cholera toxin B-Alexa 488 (Life Technologies V34403) 
Coverglass antifade reagent medium (Invitrogen, P36934) 
100 mM glycine (Sigma, G7126) in PBS 
0.1% (w/v) Poly-L-Lysine solution (Sigma, P8920) 
20% PFA in PBS (EMS, 15713-S) 
10% Triton X-100 (Fluka, 93443) 
Blocking solution-10% Goat Serum (Jackson Laboratory) in PBS-0.22um filtered 
RPMI (Irvine Scientific, 9159) 
Heat-inactivated FBS (Irvine Scientific, 300320439) 
Glutamax (Gibco, 35050-061) 
Pen-strep (Gibco, 15140-148) 
 
Procedures: 
Day Before  
1. Make complete RPMI according to recipe above. Pre-coat slides (see below). 
Remember to fill Coulter Counter cups. 
2. Precoat chamber slides: 
a. Dilute 10X poly-L-Lysine solution with sterile H2O to 1X (0.1% w/v to 
0.01% w/v) 
b. Precoat Lab-Tek II 2-well glass chamber slides with 0.01% poly-L-lysine 
(add 2 mL of 0.01% poly-L-Lysine/well for 30 min at room temperature.  
Replace the lids back on while the chamber slides are incubating.) 
3. Aspirate excess solution and sterilize the slides under UV light for 1 hr.  Leave 
the lids off.  
4. If activating with anti-CD3/anti-CD28: (If not activating, store at RT in a 
drawer to further protect from light and proceed to step 5). 
a. Dilute anti-CD3 (stock 1 mg/mL) 1:1000 and anti-CD28 (stock 1 mg/mL) 
1:100 in 1X PBS. 
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b. Add 200 µL of antibodies per chamber slide.  For control (unstimulated), 
add 200 µL of cold 1X PBS per chamber slide. 
c. Incubate chamber slides on an orbital shaker (Bellco) (gently) in the 4 °C 
walk-in cold room at a speed setting of 4, overnight.  Replace the lids 
back on to ensure sterility 
5. Day 1: wash chamber slides with 1 mL of warm complete RPMI one time.    
6. Prewarm the coated chamber slides with 200 µL of warm complete RPMI at 37 
°C for 30 or more minutes.  Leave in the incubator until seeding. 
7. Isolation of CD4+ T Cells. Follow Isolation of T cells protocol. 
8. After isolation of T cells, re-suspend the CD4+ T cells with warm complete 
RPMI to get a final concentration of T cells at 5 x 10
6
 cells/mL in complete 
RPMI media. 
9. Seed 1 mL/well dropwise by adding the cell suspension onto the 200 µL 
complete media in the well.  This equates to 5 x 10
6
 cells per well. 
a. (If activated) Final anti-CD3 concentration = 0.17 µg/mL (but is actually 
higher since plated, not suspended).Final anti-CD28 concentration = 
1.67 µg/mL (but is actually higher since plated, not suspended). 
10. Incubate at 37 °C for 30 minutes. 
11. Make 4% PFA by combining 20% PFA (1:5 dilution) in 1X  PBS. Do this in the 
chemical hood! Always make PFA fresh (i.e. the same day of experiment). 
12. Wash the cells on the chamber slides with 2 mL PBS 3 times for 2 min each, then 
immediately fix the cells in 2mL freshly made 4% PFA for 30 min at room 
temperature. Do this in the chemical hood! 
13. Rinse the samples with 2mL PBS 2 times for 2 min each, and quench cells with 
2mL 100 mM glycine in PBS (37°C) for 2 x 10 min at room temperature (gentle 
shaking in dark). 
a. This step is performed to quench aldehyde groups.  
b. Do first wash in chemical hood and dump into waste. 
c. Make glycine ahead of time and warm in the water bath (37°C) for ~15 
minutes. Quench slides on the Bellydancer (gentle shaking) with foil to 
protect from light.  
14. Wash the chamber slides with 2 mL PBS 2 times for 2 min each, and 
permeabilize the cells by using 2 mL 0.2% Triton X-100 in PBS for 5 min at 
room temperature. 
a. Stock is at 10%, so dilute 1:50 in 1X PBS.  
15. Wash the chamber slides with 2 mL PBS 3 times for 2 min each. 
16. Incubate cells in 1 mL blocking solution at room temp (gentle shaking) for 1 
hour in a humid chamber. Wash the chamber slides with PBS 3 times for 2 min 
each. 
a. Make humid chamber by thoroughly wetting a couple paper towels with 
PBS and placing at the bottom of a Tupperware container. Place the slide 
holder on top of the wet paper towels and place a few more wet paper 
towels on top. Seal tightly with the lid. 
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17. Dilute the antibody in the following manner in the dark. To properly resuspend 
antibody, flick and invert 4 times and centrifuge quickly.  
Antibody Stock Dilution Final 
Rat anti-
mouse 
gp130 
500 µg/mL 1:100 
 
5 µg/mL 
 
Rat IgG 2A 500 µg/mL 1:100 5 µg/mL 
 
18. Incubate each chamber slide with 300 µL blocking solution + 1° antibody in a 
humid chamber overnight (gentle shaking).  The slides must be protected from 
light. 
19. Wash slides 3 times for 5 minutes with PBS and incubate each chamber slide 
with 300 µL blocking solution plus 2° antibody per well at room temperature for 
2 hrs in a humid chamber.  The slides much be protected from light. To properly 
resuspend antibody, flick and invert 4 times and centrifuge quickly.  
 
20. Wash slides 3 times for 5 minutes with PBS and incubate each chamber slide 
with 300 µL blocking solution plus CTxB per well at room temperature for 1 hr 
in a humid chamber.  The slides much be protected from light. To properly 
resuspend antibody, flick and invert 4 times and centrifuge quickly.  
 
21. Prepare the ProLong medium during the last 1 hr antibody incubation by thawing 
at room temperature for 1 hr with bottle upside down (stored in -20 °C freezer). 
22. Wash the chamber slides with PBS 3 times for 2 min each. 
23. Use slide separator to remove the chamber.  Put slides on a slide holder for 
subsequent washes. 
24. Incubate the slides in 70% ethanol once for 30 sec 
25. Incubate the slides in 95% ethanol once for 30 sec 
26. Incubate the slides in 100% ethanol once for 30 sec 
27. Incubate slides in fresh xylene for 30 sec and 2 min. This means that one would 
need two fresh xylenes. 
28. Apply a small amount of antifade reagent medium mixture to the coverglass.  
Cover the slide while it is still wet. 
29. Place the slide on a flat surface in the dark to dry overnight at room temperature 
in the fume hood.  Protect from light. 
30. Day 2: Seal the cover glass to the slide with fingernail polish to prevent 
shrinkage of mounting medium and subsequent sample distortion. 
Antibody Stock Dilution Final 
Goat Anti-Rat IgG (Alexa 555)  2 mg/mL 1:200 10 µg/mL 
Antibody Stock Dilution Final 
Cholera Toxin B (Alexa 488) 1,000 µg/mL 1:166 6 µg/mL 
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31. After sealing, let it dry for at least 15 min, then store the slide upright in a slide 
box at -20°C.  Desiccant may be added to the box to ensure that the slide remains 
dry.  
32. Examine sample under fluorescence microscopy. Use Pearson’s correlation and 
Mander’s coefficient for co-localization analysis. 
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APPENDIX F 
 
WESTERN BLOT 
 
Purpose: To determine the presence of a specific protein (gp130) in a sample using 
a primary antibody to tag the desired protein and a secondary antibody to visualize 
the marked protein. 
 
Reagents: 
SDS running buffer (Expedeon NXB60500) 
Pyronin 5X Sample Buffer 
--40% glycerol (Sigma, 119H0206), 25% β-mercaptoethanol (ProPure, 
3009B297), 12% SDS (Fisher, BP166-100), 0.31 M Trish Base pH 6.8 (Fisher, 
cat# BP154-1), 25 mM EDTA (Sigma, ED455-500G), 0.1% Pyronin Y (BioRad, 
161-0425)  
1X Tris-Glycine and 14% methanol 
--To make 2 L, mix 200 mL of 10X Tris-Glycine (Amresco 0783), 280 mL of 
methanol (Fisher, cat# A433P-4), and 1520 mL of double distilled water 
1X PBS-Tween 
--Dissolve one bottle of 10X Dulbecco’s Phosphate-Buffered Saline (Gibco, 
cat#21600-069) in one liter of double distilled water and then add 10 g of Tween-
20 (Fisher, cat#BP337-500). The Tween-20 should be added directly into the 
PBS on the scale due to the viscosity of the Tween 20. Dilute this solution down 
to 1X by adding 100 mL of 10X PBS Tween into 900 mL of double distilled 
water.  
4-20% Tris-Glycine gel (Expedeon NXG42012) 
Magic Mark XP Western Standard (invitrogen, LC5620) 
Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific, 34095) 
Immobilon membrane (Millipore, #6MW-2020) (dimensions of 7.4 cm across and 8.5 
cm in length) 
Filter paper (MidSci, #IPVH00010) (dimensions of 10 cm x 10 cm) 
Rabbit anti-mouse gp130 (Santa Cruz sc-656) 
Goat anti-rabbit IgG peroxidase conjugated (KPL 074-1506) 
 
Preparation: 
Make Running Buffer and Transfer buffer and cool before use 
o Can be re-used several times 
Thaw samples on ice from -80ºC (usually takes about 15 minutes) 
Label the top of 0.6 ml eppy tubes 
Prepare western blot template sheet. 
 
Sample Preparation: 
1. The dye used for the sample dilutions is 5X Pyronin. Dilute the dye down to 1X. 
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 a. For example, if you have a total volume of sample + buffer + dye=10, use 2 µl 
dye  (10/5=2) 
2. With the aid of the western blot template, dispense the correct amount of dye and 
double distilled water into the eppy tubes and add the sample last. 
3. Flick the ends of the tubes for basic mixing and then quick spin. 
4. Boil the samples for 5-10 min depending on the volume of the samples at 98ºC (25 μL 
volumes are boiled for 10 min). Do not boil the marker. 
5. Once boiling is complete, flick the ends of the tube for basic mixing and then quick 
spin. 
 
Gel unit set up: 
6. While the samples are boiling, take the pre-made gel (4-20%) and carefully rip off and 
discard the white tape. 
7. When clipping the gels or the white sheet to the gel apparatus, the broad side of the 
clip should be facing you and broad ends face outside on all 4 clips. See figure for visual 
clarification.   
 
 
1. White, metal sheet 
2. Proper orientation of clips on the gel trough 
 
8. For attaching one gel, attach the white, metal sheet to adjacent side (make sure that the 
sheet is pressed all the way to the bottom of the well and against the back of the 
apparatus). Attach the gel in the same fashion as the white sheet with the gel pressed all 
the way to the bottom of the trough and against the back of the unit. 
9. Pour running buffer in between the gel and the apparatus until a small amount of 
buffer leaks over the top of the gel. 
1 2 
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10. Check to see if there are any leaks by observing the level of the buffer behind the 
gel. 
11. Repeat steps 9 and 10 for the white sheet or the adjacent gel. 
12. Once there are no leaks, fill the bottom of the trough on both sides with running 
buffer up to the top mark. (Cover middle hump) 
13. Load the samples into their respective wells. The gel should be loaded in the cold 
room. 
14. Close the unit with the lid and check the leads and make sure black-to-black and red-
to-red. 
15. In the cold room, run the gel at 125 V until the marker is just above the indention 
where the white tape was removed (The running of the gel takes about two hours and 
increase the power, current, and time in the power unit so that these factors do not affect 
the voltage). 
16. Before leaving the cold room, make sure 125 V is reached and check the gel after 10 
min to make sure the gel is running properly. If the gel is running properly, the marker 
and the dye should be running evenly down the gel (run for ~2hrs).  
 
Gel Transfer: 
17. Take the gel transfer unit in a staining tray and pour transfer buffer into the trough. 
18. Take the cassette and lay it open. 
19. Put the thick sponge on the black side of the cassette and place the thin sponge on the 
white side of the cassette.  
20. Place a piece of filter paper on each sponge. 
21. Pour transfer buffer in the trough to keep the thick sponge and filter paper wet. It is 
not necessary for the thin sponge to be wet. 
22. Take the gel plate out of the running trough and transfer the running buffer into the 
bottle for reuse. 
23. Crack open the plate with a scalpel between the markings on the plate all around by 
keeping the large side of the gel down. 
24. Cut the wells out of the gel and cut just above the bottom to allow separation of the 
gel from the plastic. 
25. Carefully separate the gel from the plate and cut a mark on the gel to keep track of 
the location of lane one. 
26. Place the gel in transfer buffer for 5 min to allow it to equilibrate. 
27. Place the gel on the filter paper with lane one on the right side to ensure that the 
protein will face the membrane. 
28. Take the membrane out of the sandwich of protective paper with forceps and wet the 
membrane in a dish of methanol for about 3 min. 
29. Place the membrane on top of the gel and roll out the air bubbles that are between the 
gel and the membrane (the very bottom of the membrane may be touched when rolling). 
30. Place the second filter paper on top of the membrane and roll out the remaining air 
bubbles. 
31. Place the thin sponge on top of the filter paper and carefully close the cassette to 
prevent the creation of more air bubbles.  
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32. Place the cassette in the transfer unit with the hinges facing the top and the black side 
facing the back of the unit. 
33. Put a stir bar into the transfer unit. 
34. Fill the unit with transfer buffer just enough to cover the hinges of the cassette 
(ignore the maximum level indicator on the unit). 
35. Place the unit in the cold room on the stir plate and set to a speed setting of about 4. 
36. Give the unit a final tap and connect black to the back of the unit and red to the front 
of the unit. 
37. Set the current to 400 mA (0.4 A) and allow the transfer to take place for 90 min. 
 
Blocking: 
Note: For experiments requiring the use of BSA, follow the same protocol as dried milk.  
Refer to the manufacturer’s data sheet to see if BSA or dried milk should be used. 
 
38. At the end of the transfer, make fresh 4% nonfat dry milk/ 1XPBS (0.1%)Tween in a 
50 mL tube (30 mL of 1X PBS (0.1%)Tween and 1.2 g of pre-weighted milk powder). 
Mix gently by inversion. 
39. Pour milk into a dish and keep ready to transfer the membrane into it. 
40. Open the transfer unit, place membrane into the milk mixture with broad-nosed 
forceps, and put transfer buffer back into bottle for reuse (make sure side of the 
membrane with the protein is facing up). 
41. Place membrane dish on the shaker (Stovall, Belly Dancer) for 1 hr at room 
temperature at a speed setting of about 6. 
 
Primary Antibody: 
42. Prepare a fresh dish of 1.2 g of dry milk and 30 mL of 1X PBS (0.1%)Tween about 
5-10 min before blocking is complete. (can do 20 ml if trying to conserve antibody). 
43. Pour out milk from previous steps and pour in fresh milk. 
44. Now, add the appropriate volume of the primary antibody based on the 
manufacturer’s recommended dilution and the volume added to the dish. 
45. Close the lid of the dish and shake at an intensity of 3 in the cold room overnight. 
 
Washing: 
46. The next day take the membrane and give it a quick wash with 1X PBS 
(0.1%)Tween. A quick wash is simply pouring out the solution and adding fresh 1X PBS 
(0.1%)Tween. Keep on the shaker at room temperature for 10 min, and let it shake at a 
speed setting of about 6. Do 3 washes! 
 
Secondary Antibody: 
47. Make 30 mL of milk/PBS (0.1%)Tween and pour into the dish after the second wash 
to ensure that it is fresh (1.2 g of dry milk and 30 mL of 1X PBS (0.1%)Tween). 
48. After the washing is complete, place the membrane into the fresh milk/1XPBS 
(0.1%)Tween mixture and add the correct amount of secondary antibody depending on 
the manufacturer’s suggested dilution and the volume of the dish. 
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49. Set the dish on the shaker for one hour at room temperature with a shaking speed of 
about 3. 
50. Once the shaking is complete, repeat washing with 1X PBS (0.1%)Tween three 
times (Step 46). 
 
Developing: 
51. During the washing, turn on the camera and the imager. Then make sure the imager 
is set to CHEMI. 
52. After the 2
nd
 wash is complete, cut an acetate sheet into two halves and remove the 
black sheet in between. 
53. Mix 0.25 mL of chemiluminescent super signal reagent A with 0.25 mL of reagent B 
in an eppy tube and mix gently by pipetting (Place the tube in the dark until use because 
this mixture is sensitive to light). 
54. Now transfer the membrane with forceps in between the layers of the acetate sheet 
and squirt the developing solution on the top of the membrane. 
55. Slowly close the top layer so that the solution gets evenly distributed on the 
membrane. 
56. Expose to light for five minutes and then transfer the membrane onto a clean acetate 
sheet. The new acetate sheet does not need to be protected from light. 
57. Transfer into the imager and image immediately. 
 
Imaging: 
58. Select the Quantity One program on the desktop. 
59. Select the scanner- click on chemidoc.xrs (there is only one option). 
60. Select the option of chemiluminescences and live focus. 
61. Focus with a printed sheet and set the iris as you need for brightness. Zoom and 
focus, as you need for clarification. 
62. Freeze. Put the gel in the imager and zoom and freeze again. Close the door. 
63. Click on Live Acquire. 
64. Starting Exposure time -30 sec. 
       Total Exposure time-150 sec. 
       Number of exposures- 5 
65. Imager takes 5 pictures in 150 sec. (These settings can be adjusted as needed).  
66. Turn off machine (2 power buttons) and clean the inside with distilled water and 
wipe dry. Remember to sign out. 
 
 
Expected Results: 
Once the membrane is developed, bands should appear in the size range of the desired 
protein based on the molecular weight marker.  The full marker should also be visualized 
when developed.  
 
Storage Conditions of Products and Reagents:  
 Samples should be kept on ice at all times. 
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 The developing solution should be protected from light until it is ready for use. 
The developing kit should be stored at 4ºC. 
 Running buffer and Transfer buffer should be stored at 4ºC. 
 1X PBS (0.1%)Tween may be stored at room temperature. 
 BSA should be stored at 4ºC, but the milk powder can be stored at room 
temperature. 
 
Notes:  
 Milk/BSA solution should always be make fresh about 10 min before use. 
 Gloves should be worn at all times to preserve the integrity of the membrane and 
for protection of the hands from harmful reagents. 
 For analysis of gp130 protein expression, 4 µg of protein was electrophoresed 
with a 1° antibody dilution of 1: 2,000 in milk and 2° antibody dilution of 
1:10,000 in milk.  
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APPENDIX G 
 
GP130 DIMERIZATION 
 
Purpose: To measure the ability of gp130 molecules to form homodimers as a 
means of assessing function.  
 
Reagents: 
Recombinant IL-6 (Biolegend 575704) 
Bissulfosuccinimidyl suberate (BS
3
) (Thermo Scientific # 21586) 
Glycine (Sigma, G7126) 
Homogenization Buffer (See appendix H) 
Benzonase (Sigma E1014-25KU) 
 
Procedure: 
1. Isolate CD4+ T cells according to Appendix A: Isolation of CD4+ T cells 
Miltenyi bead/column.  
a. Use 7 million cells per mouse in 1 mL complete RPMI (need two samples-
one stimulated with IL-6, one unstimulated). 
2. Stimulate with 100 ng/mL IL-6 for 10 minutes at 37ºC. 
3. Spin down at 350g for 5 minutes, aspirate supernatant, wash with 10 mL PBS, 
spin down, resuspend in 5 mL of 3 mM bis(sulfosuccinimidyl)suberate (BS
3
) ( 
MW=572.4) in ice cold Ca
2+
, Mg
2+
 free PBS for 2 hours at 4
o
C (8.60 mg BS
3
 in 5 
mL). 
a. This crosslinks proteins that are in contact with each other. 
4. Quench with 10 mL of 250 mM glycine in PBS for 5 min at 4oC. 
5. Spin down at 350 x g for 5 minutes, aspirate supernatant, wash with 10 mL PBS, 
spin down, aspirate supernatant. 
6. Add 100 µL of homogenization buffer with 1 µl benzonase to each tube and 
transfer to a 0.6 mL epi tube.  
7. Incubate the total lysate in ice for 30 min.  
8. Centrifuge at 16, 000 x g at 4°C for 20 min. 
9. Transfer the supernatant (lysate) to clean epi-tube, mix. 
10. Aliquot (30 l) and save aliquots at -80°C for further protein estimation using 
Coomassie Plus and immunoblotting. 
Notes: 
 Dimers on western blot should be twice the size of the gp130 band (should 
appear at 260 kDa).  Unstimulated cells should not have a dimer band and can be 
used for control. 
 Gel for western blot should be run for approximately 4-5 h at 125 V, and transfer 
should be overnight at 400 mAmps.  Make sure to incubate the gel in transfer 
buffer for ~15-30 minutes before beginning the transfer. 
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 APPENDIX H 
HOMOGENIZATION BUFFER 
 
Purpose: To homogenize naïve or stimulated CD4+ T cells for western blot 
analysis.  
 
Homogenization Buffer Part A: Can be made ahead and stored at 4°C for a couple days 
or aliquoted and stored at -20°C. 
 
Part B:  Make the day of use  
For 1 mL of complete buffer, use 960 µl Part A + ingredients listed below. For 5 mL, 
add 4,747 µl Part A + ingredients listed below. 
Component Catalog 
Number 
Volume for 5 
mL 
Volume for 1 
ml 
Final 
Concentration 
Protease Inhibitor 
Cocktail 
Sigma 
(P8340) 
0.2 mL 40 µl  
2 β-mercaptoethanol 
14.2 M 
Amresco 
(M131) 
3.5 µl 0.7 µl 10 mM 
Halt Phosphatase 
Inhibitor (100X) 
Thermo 
Scientific 
(78428) 
50 µl 10 µl 1X 
 
Component Catalog 
Number 
Volume for 
10 mL 
Final 
Concentration 
500 mM Tris-HCL (pH 7.2)  
(6.1 g/100 mL) 
Fisher Scientific 
(BP153) 
1 mL 50 mM 
1 M Sucrose 
(34.23g/100mL)  
Sigma (S9378) 2.5 mL 250 mM 
200 mM EDTA (pH 7.6)   
4.162g in 50mL 
Sigma (ED4SS) 0.1 mL 2 mM 
100 mM EGTA (pH 7.5) 
0.38 g/10 mL-add NaOH to get 
it to dissolve and bring pH to 
7.5 
Sigma (34596) 0.1 mL 1 mM 
10% Triton X-100 
2 mL up to 20 mL ddH20 
Sigma (T6878) 1 mL 1% 
ddH20  4.7 mL  
